The FDA has approved neoadjuvant durvalumab plus chemotherapy, followed by adjuvant durvalumab, for select resectable non–small cell lung cancer. The FDA has approved durvalumab (Imfinzi) in combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by single-agent durvalumab as adjuvant treatment after surgery, for adult patients with resectable (tumors ≥4 cm and/or node positive) non–small cell lung cancer and no known EGFR mutations or ALK rearrangements.1.

FDA Approves Perioperative Durvalumab Plus Chemotherapy in Resectable NSCLC

Matthew Galsky, MD, discusses the disease-free survival of nivolumab vs placebo in patients with high-risk muscle-invasive bladder cancer. Matthew Galsky, MD, professor of medicine (hematology and medical oncology), director of genitourinary medical oncology, codirector of the Center of Excellence for Bladder Cancer, and associate director for Translational Research at The Tisch Cancer Institute at Mount Sinai in New York, discusses the efficacy of adjuvant nivolumab (Opdivo) in the phase 3 CheckMate 274 trial (NCT02632409).

Nivolumab Shows Improved DFS in ITT and PD-L1–High Bladder Cancer

The FDA-approved regimen is for neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab in patients with resectable non–small cell lung cancer. The FDA approved durvalumab (Imfinzi) with platinum-containing chemotherapy in patients with resectable non–small cell lung cancer (NSCLC) without EGFR mutations or ALK rearrangements. This approval is supported...

Neoadjuvant/Adjuvant Durvalumab Scores FDA Approval in Resectable NSCLC

Researchers may have uncovered how combination immunotherapies targeting the immune checkpoints PD-1 and LAG-3 may work together to activate immune responses in patients with melanoma, according to two recent studies published by Cillo et al and Andrews et al in Cell. The findings may shed light on why these combination therapies can improve outcomes in patients with melanoma compared with monotherapies targeting only PD-1.

Combination Immunotherapies May Boost T-Cell Responses in Patients With Melanoma

Researchers have demonstrated that adding metastasis-directed radiation therapy to standard-of-care chemotherapy may improve progression-free survival in patients with oligometastatic pancreatic cancer, according to a recent study published by Ludmir et al in the Journal of Clinical Oncology and previously presented at the 2024 ASCO Gastrointestinal Cancers Symposium (Abstract 603). Background.

Metastasis-Directed Radiation Therapy Plus Chemotherapy in Oligometastatic Pancreatic Cancer

Turnstone Biologics is narrowing the focus of phase 1 trials of its lead tumor-infiltrating lymphocyte (TIL) therapy, with cutaneous melanoma and breast cancer no longer in the mix. The program, dubbed TIDAL-01, has been undergoing two phase 1 trials, including the STARLING study evaluating the therapy for the treatment of...

Turnstone narrows cell therapy focus to 'high unmet need' tumor indications

Las Vegas, NV

Contributors represent independent, third-party users who have joined our contributor program and self-verified their accounts. They have also demonstrated their experience writing hard news for other outlets. Contributors are expected, like all users, to adhere to our Community Standards.

contributor

Bellingham Metro News

LAS VEGAS, NEVADA - A magnitude 4.4 earthquake struck areas near Las Vegas on Tuesday night, according to the United States Geological Service (USGS). The quake, which occurred at 8:06 p.m., was centered approximately 45 minutes from Las Vegas, near Indian Springs.

Magnitude 4.4 Earthquake Shakes Areas Near Las Vegas

In this episode of Targeted Talks, Edwin Choy, MD, PhD, discussed the FDA approval of afamitresgene autoleucel for the treatment of patients with advanced synovial sarcoma. In this episode of Targeted Talks, Edwin Choy, MD, PhD, director of the sarcoma program at the Division of Hematology Oncology at Massachusetts General Hospital, a founding member of Mass General Brigham, and associate professor of medicine at Harvard Medical School, delves into the recent approval of afamitresgene autoleucel (afami-cel; Tecelra) for the treatment of patients with advanced synovial sarcoma.

Breaking New Ground in Synovial Sarcoma: Choy on the FDA Approval of Afami-cel

Crexont kept symptoms at bay for an extra 30 minutes a day when compared with other Parkinson’s drugs. Amneal Pharmaceuticals Inc. announced yesterday the FDA approval for Parkinson’s drug Crexont (carbidopa and levodopa) via a news release on their website. This novel medication, formerly known as IPX203, combines two common drugs into one capsule.

FDA Approval Granted for Novel Parkinson’s Treatment

Gilead wins on new company acquisition with accelerated approval for autoimmune liver disease drug. US big pharma Gilead Sciences has won an accelerated US FDA approval for peroxisome proliferator-activated receptor delta agonist seladelpar (Livdelzi) for treatment of primary biliary cholangitis in combination with ursodeoxycholic acid. The accelerated approval comes after...

Gilead gains accelerated FDA approval for rare liver disease treatment

Mazyar Shadman, MD, MPH, discusses the investigation of sonrotoclax in the CELESTIAL-TNCLL trial in treatment-naïve chronic lymphocytic leukemia. Mazyar Shadman, MD, MPH, Innovators Network Endowed Chair, associate professor, Clinical Research Division, Fred Hutchinson Cancer Center; associate professor, Medical Oncology Division, University of Washington School of Medicine, discusses the mechanism of action of sonrotoclax (BGB-11417), highlighting the rationale for combining the agent with zanubrutinib (Brukinsa) in the phase 3 CELESTIAL-TNCLL trial (NCT06073821) in patients with treatment-naive chronic lymphocytic leukemia (CLL).

Dr Shadman on the Investigation of Sonrotoclax Combination Therapy in Treatment-Naive CLL

Community Voices represent independent, third-party users who have joined our contributor program but not yet verified their accounts. Community Voices are expected, like all users, to adhere to our Community Standards.

community_voice

The Lens

This year’s area of low oxygen in the Gulf of Mexico is larger than average, the National Oceanic and Atmospheric Administration (NOAA) announced on Thursday. The “dead zone” is approximately 6,705 square miles , as measured last week. Within NOAA’s 38 years of measuring the dead zone, this year’s assessment marks the 12th-largest area of low to no oxygen, which can kill fish and marine life.

Gulf ‘dead zone’ larger than average, larger than expected for 2024, scientists announce

Artificial intelligence (AI) has yet to transform the drug development process, but some efforts seem more promising than others. On Monday, cancer research giant Memorial Sloan Kettering and life sciences AI pioneer Absci announced a first-of-its kind partnership to discover six novel therapies for cancer using generative AI, hoping to bring new drugs to clinical trials faster than with typical drug development efforts.

Absci and Memorial Sloan Kettering partner to search for cancer drugs using AI

Cooking With Maryann

This recipe is sooo tasty! It truly is for garlic lovers! It involves sautéing onions and mushrooms in butter and oil until golden, then adding wine to reduce. Garlic, thyme, and parsley are stirred in for flavor, followed by seasoning with salt and pepper. The dish is garnished with additional parsley and served warm, making for a savory, aromatic side. Here's what you'll need to make it:

Garlic Mushrooms in Brown Butter Herb Sauce

Reuters

(Reuters) -The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences' liver disease treatment, Livdelzi, which it gained through a $4.3 billion buyout of CymaBay Therapeutics earlier this year.

Gilead gets US FDA approval for inflammatory liver disease drug

Health

Medically reviewed by Marla Anderson, MDMedically reviewed by Marla Anderson, MDNon-small cell lung cancer (NSCLC) is a type of cancer that begins in the tissues of the lungs. About 80-85% of all lung cancer cases in the United States are classified as NSCLC. NSCLC occurs when the cells that line the surface of the lung airways change and mutate. When these abnormal cells rapidly divide and multiply, they lead to cancer. The most common cause of NSCLC is smoking, with about 90% of lung cancer cases being related to tobacco smoke exposure. It is possible to be diagnosed with NSCLC if you...

What Causes Non-Small Cell Lung Cancer (NSCLC)?

In an interview, Marc Braunstein, MD, PhD, reviewed key updates in multiple myeloma for chimeric antigen receptor (CAR) T-cell and bispecific antibody therapy, and discussed planning for transition of care. Marc Braunstein, MD, PhD. Associate Professor, Department of Medicine. Fellowship Program Director, Hematology/Oncology. Codirector, Hematology-Oncology System. NYU Grossman Long Island...

Expert Insights on Important Updates in Multiple Myeloma With Marc Braunstein, MD, PhD

Los Angeles, CA

Herbie J Pilato

It's been four decades since Emmy-nominated actor Lloyd Haynes died of lung cancer at only 52 years old. Best known for his compassionate performance as history teacher Pete Dixon on television's groundbreaking, academic-geared dramedy, Room 222 (ABC, 1969-1974), Haynes was beloved by his fans, family, friends and colleagues alike. This is his story.

In Memory of 'Room 222' TV Actor Lloyd Haynes: 4 Decades After His Tragic Death From Lung Cancer

Findings from the phase 3 E1910 study showed that blinatumomab extended overall survival when added to chemotherapy vs chemotherapy alone in B-cell precursor acute lymphoblastic leukemia. An overall survival (OS) benefit was observed when the immunotherapy blinatumomab (Blincyto) was added to consolidation chemotherapy in patients with B-cell precursor acute lymphoblastic...

Blinatumomab Improves 3-Year Survival in B-ALL vs Chemotherapy

(Reuters) - The U.S. Food and Drug Administration approved AstraZeneca's blockbuster cancer drug, Imfinzi, for the treatment of patients with a type of non-small cell lung cancer on Thursday.

US FDA approves AstraZeneca's non-small cell lung cancer treatment

NewsBreak

Evaluating Camu Camu With Ipilimumab and Nivolumab in mRCC

Regina Barragan-Carrillo, MD, discusses a pilot study evaluating the use of camu camu in combination with ipilimumab and nivolumab for treating metastatic renal cell carcinoma. Regina...

Evaluating Camu Camu With Ipilimumab and Nivolumab in mRCC

Comments / 0